Please login to the form below

Not currently logged in
Email:
Password:

Astellas files patent suit against Sandoz

Astellas Pharma has filed a lawsuit against generics manufacturer Sandoz relating to a version of Astellas' organ transplantation drug, Prograf, which Sandoz plans to market in Canada

Astellas Pharma has filed a lawsuit against Sandoz, the generic division of Novartis, relating to a version of Astellas' Prograf (tacrolimus hydrate) that Sandoz plans to market in Canada.

The suit, which was filed in the Federal Court of Canada, contains an order prohibiting marketing approval from the Canadian Minister of Health for Sandoz's generic tacrolimus hydrate before the expiration of Astellas' patent for the therapy.

Prograf is currently approved in Canada and elsewhere as an immunosuppressant following organ transplantation.

Sandoz previously launched a generic version of Prograf in the US August 2009.

14th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics